Immunotherapy plus an investigational cancer drug improves anti-tumor effects

An investigational therapy for solid tumors could be especially effective when combined with immunotherapy to target a specific kind of cancer cell, a research team at Duke and Harvard have found. Led by Lee Zou, Ph.D., chair of Duke’s Department of Pharmacology & Cancer Biology, the researchers focused on the way some cancer cells impede normal DNA repair to fuel tumor formation. This phenomenon is known as defective DNA mismatch repair.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news